- cafead Nov 09, 2018 at 12:22: PM
via Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc’s infection-fighting treatment, Neulasta, at a 33 percent discount.
article source
article source
-
Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page
Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount
- Thread starter cafead
- Start date
<
Similar threads